Rational Drug Delineation: A Global Sensitivity Approach Based on Therapeutic Tolerability to Deviations in Execution


Noncompliance to therapeutic regimen is a real public health problem with tremendous socioeconomic consequences. Instead of direct intervention to patients, which can add extra burden to the already overloaded health system, alternative strategies oriented to drugs’ own properties turns to be more appealing. The aim of this study was establish a rational way to delineate drugs in terms of their “forgiveness”, based on drugs PK/PD properties. A global sensitivity analysis has been performed to identify the most sensitive parameters to dose omissions. A Comparative Drug Forgiveness Index (CDFI), to rank the drugs in terms of their tolerability to non compliance, has been proposed. The index was applied to a number of calcium channel blockers, namely benidipine, nivaldipine, manidipine and felodipine. Using the calculation, benedipine and manidipine showed the best performance among those considered. This result is in accordance with what has been previously reported. The classification method developed here proved to be a powerful quantitative way to delineate drugs in terms of their forgiveness and provides a complementary decision rule for clinical and experimental studies.

Share and Cite:

D. Gohore, F. Fenneteau, O. Barrière, J. Li and F. Nekka, "Rational Drug Delineation: A Global Sensitivity Approach Based on Therapeutic Tolerability to Deviations in Execution," Pharmacology & Pharmacy, Vol. 1 No. 2, 2010, pp. 42-52. doi: 10.4236/pp.2010.12007.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] B. Vrijens, G. Vincze, P. Kristanto, J. Urquhart and M. Burnier, “Adherence to Prescribed Antihypertensive Drug Treatments: Longitudinal Study of Electronically Compiled Dosing Histories,” British Medical Journal, Vol. 336, No. 7653, 2008, pp. 1114-1117.
[2] J. Urquhart, “Patient Non-Compliance with Drug Regimens: Measurement, Clinical Correlates, Economic Impact,” Eur Heart J., Vol. 17, No. (Suppl. A), 1996, pp. 8-15.
[3] R. Düsing, “Adverse Events, Compliance, and Changes in Therapy,” Current Hypertension Reports, Vol. 3, No. 6, 2001, pp. 488-492.
[4] J. Urquhart, “Pharmacodynamics of Variable Patient Compliance: Implications for Pharmaceutical Value,” Advanced Drug Delivery Reviews, Vol. 33, No. 3, 1998, pp. 207-219.
[5] P. Girard, L. B. Sheiner, H. Kastrissios and T. F. Blaschke, “Do we Need Full Compliance Data for Population Pharmacokinetic Analysis?” J Pharmacokinetics and Biopharmaceutics, Vol. 24, No. 3, 1996, pp. 265-282.
[6] A. Blesius, S. Chabaud, M. Cucherat, P. Mismetti, J. P. Boissel and P. Nony, “Compliance-Guided Therapy: A New Insight into the Potential Role of Clinical Pharmacologists,” Clinical Pharmacokinetics, Vol. 45, No. 1, 2006, pp. 95-104.
[7] J. Li and F. Nekka, “A Probabilistic Approach for the Evaluation of Pharmacological Effect Induced by Patient Irregular Drug Intake,” Journal of Pharmacokinetics and Pharmacodynamics, Vol. 36, No. 3, 2009, pp. 221-238.
[8] G. D. Gohore Bi, J. Li and F. Nekka, “Antimicrobial Breakpoint Estimation Accounting for Variability in Pharmacokinetics,” Theoretical Medicine and Biology, Vol. 26, No. 6, 2009, p. 10.
[9] B. Vrijens, E. Goetghebeur, E. de Klerk, R. Rode, S. Mayer and J. Urquhart, “Modelling the Association between Adherence and Viral Load in HIV-Infected Patients,” Statistics in Medicine, Vol. 24, No. 17, 2005, pp. 2719-2131.
[10] Y. Huang, S. L. Rosenkranz and H. Wu, “Modeling HIV Dynamics and Antiviral Response with Consideration of Time-Varying Drug Exposures, Adherence and Phenotypic Sensitivity,” Mathematical Biosciences, Vol. 184, No. 2, 2003, pp. 165-186.
[11] E. Hénin, B. You, B. Tranchand, G. Freyer and P. Girard, “Issues of the Study of Patient Compliance to Treatment with Oral Anticancer Chemotherapy: Advantages of Phar- macokinetics-Pharmacodynamics Modelisation,” Therapie, Vol. 62, No. 2, 2007, pp. 77-85.
[12] J. Li and F. Nekka, “A Pharmacokinetic Formalism Explicitly Integrating the Patient Drug Compliance,” Journal of Pharmacokinetics and Pharmacodynamics, Vol. 34, No. 1, 2007, pp. 115-139.
[13] J. Li, C. E. Petit-Jetté, D. Gohore Bi, F. Fenneteau, R. J. Del Castillo and F. Nekka, “Assessing Pharmacokinetic Variability Directly Induced by Drug Intake Behaviour through Development of a Feeding Behaviour-Pharma- cokinetic Model,” Journal of Theoretical Biology, Vol. 251, No. 3, 2008, pp. 468-479.
[14] P. Nony and J. P. Boissel, “Use of Sensitivity Functions to Characterise and Compare the Forgiveness of Drugs,” Clinical Pharmacokinetics, Vol. 41, No. 5, 2002, pp. 371- 380.
[15] F. Fenneteau, J. Li and F. Nekka, “Assessing Drug Distribution in Tissues Expressing P-Glycoprotein Using Physiologically Based Pharmacokinetic Modeling: Identification of Important Model Parameters through Global Sensitivity Analysis,” Journal of Pharmacokinetics and Pharmacodynamics, Vol. 36, No. 6, 2009, pp. 495-522.
[16] F. Fenneteau, P. Poulin and F. Nekka, “Physiologically Based Predictions of the Impact of Inhibition of Intestinal and Hepatic Metabolism on Human Pharmacokinetics of CYP3A Substrates,” Journal of Pharmaceutical Sciences, Vol. 99, No. 1, 2010, pp. 486-514.
[17] A. Saltelli, S. Tarantola, F. Campolongo and M. Ratto, “Sensitivity Analysis in Practice: A Guide to Assessing Scientific Model,” Wiley, New York, 2004.
[18] A. Saltelli, M. Ratto, S. Tarantola and F. Campolongo, “Sensitivity Analysis for Chemical Models,” Chemical Reviews, Vol. 105, No. 7, 2005, pp. 2811-2828.
[19] J. Zàdor, I. G. Zsély, T. Turanyi, M. Ratto, S. Tarantola and A. Saltelli, “Local and Global Uncertainty Analyses of a Methane Flame Model,” Journal of Physical Chemistry A, Vol. 109, No. 43, 2005, pp. 9795-9807.
[20] P. Girard, T. F. Blaschke, H. Kastrissios, L. B. Sheiner, “A Markov Mixed Effect Regression Model for Drug Compliance,” Statistics in Medicine, Vol. 17, No. 20, 1998, pp. 2313-2333.
[21] J. Sun, H. N. Nagaraj, N. R. Reynolds, “Discrete Stochastic Models for Compliance Analysis Based on an AIDS Clinical Trial Group (ACTG) Study,” Biomedicine Journal, 2007, Vol. 49, No. 5, pp. 731-741.
[22] S. Shimada, Y. Nakajima, K. Yamamoto, Y. Sawada and T. Iga, “Comparative Pharmacodynamics of Eight Calcium Channel Blocking Agents in Japanese Essential Hypertensive Patients,” Biological and Pharmaceutical Bulletin, Vol. 19, No. 3, 1996, pp. 430-437.
[23] K. Yao, K. Nagashima and H. Miki, “Pharmacological, Pharmacokinetic, and Clinical Properties of Benidipine Hydrochloride, a Novel, Long-Acting Calcium Channel Blocker,” Journal of Pharmacological Sciences, Vol. 100, No. 4, 2006, pp. 243-261.
[24] H. Y. Yun, M. H. Yun, W. Kang and K. I. Kwon, “Pharmacokinetics and Pharmacodynamics of Benidipine Using a Slow Receptor-Binding Model,” Journal of Clinical Pharmacy and Therapeutics, Vol. 30, No. 6, 2005, pp. 541-547.
[25] R. B. Haynes, D. L. Sackett, E. Gibson, H. Wand, R. S. Roberts, et al., “Improvement of Medication Compliance in Uncontrolled Hypertension,” Lancet, Vol. 1, No. 7972, 1976, pp. 1265-1268.
[26] A. Saltelli, M. Ratto, T. Andres, F. Campolongo, J. Cariboni, D. Gatelli, et al., “Global Sensitivity Analysis: The Primer,” Wiley, Chichester, 2008.
[27] Y. Nakajima, K. Yamamoto, S. Shimada, H. Kotaki, Y. Sawada and T. Iga, “In Vitro-in Vivo Correlation of Pharmacodynamics of Felodipine in Essential Hypertensive Patients Based on an Ion-Channel Binding Model,” Biological and Pharmaceutical Bulletin, Vol. 19, No. 8, 1996, pp. 1097-1099.
[28] R. Kirsten, K. Nelson, D. Kirsten and B. Heintz, “Clinical Pharmacokinetics of Vasodilators,” Part I. Clinical pharmacokinetics, Vol. 34, No. 6, 1998, pp. 457-482.
[29] O. Nakajima, H. Akioka and M. Miyazaki, “Effect of the Calcium Antagonist Benidipine Hydrochloride on 24-h Ambulatory Blood Pressure in Patients with Mild to Moderate Hypertension in a Double-Blind Study against Placebo,” Arzneimittelforschung, Vol. 50, No. 7, 2000, pp. 620-625.
[30] G. Mancia, S. Omboni, E. Agabiti-Rosei, R. Casati, R. Fogari, G. Leonetti, et al., “Antihypertensive Efficacy of Manidipine and Enalapril in Hypertensive Diabetic Patients,” Journal of Cardiovascular Pharmacology, Vol. 35, No. 6, 2000, pp. 926-931.
[31] S. R. O. Antonicelli, D. C. Giovanni, R. Ansuini, A. Mori, R. Gesuita, G. Parati, et al., “Smooth Blood Pressure Control Obtained with Extended-Release Felodipine in Elderly Patients with Hypertension: Evaluation by 24-Hour Ambulatory Blood Pressure Monitoring,” Drugs Aging, Vol. 19, No. 7, 2002, pp. 541-551.
[32] G. Mancia, S. Omboni, G. Parati, D. L. Clement, W. E. Haley, S. N. Rahman, et al., “Twenty-Four Hour Ambulatory Blood Pressure in the Hypertension Optimal Treatment (HOT) Study,” Journal of Hypertension, Vol. 19, No. 10, 2001, pp. 1755-1763.
[33] S. Omboni, R. Fogari and G. Mancia, “A Smooth Blood Pressure Control is Obtained over 24 h by Delapril in Mild to Moderate Essential Hypertensives,” Blood Press, Vol. 10, No. 3, 2001, pp. 170-175.
[34] A. Roca-Cusachs and F. Triposkiadis, “Antihypertensive Effect of Manidipine,” Drugs, Vol. 65, No. (Suppl. 2), 2005, pp. 11-19.
[35] J. Urquhart, “Erratic Patient Compliance with Prescribed Drug Regimens: Target for Drug Delivery Systems,” Clinical Pharmacology & Therapeutics, Vol. 67, No. 4, 2000, pp. 331-334.
[36] J. P. Boissel and P. Nony, “Using Pharmacokinetic-Pharmacodynamic Relationships to Predict the Effect of Poor Compliance,” Clinical Pharmacokinetics, Vol. 41, No. 1, 2002, pp. 1-6.
[37] S. M. Cheer and K. McClellan, “Manidipine: A Review of its Use in Hypertension,” Drugs, Vol. 61, No. 12, 2001, pp. 1777-1799

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.